2025-2034 Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Evolution: Disruptions, Innovations, and Untapped Opportunities

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Through 2025?
The market encompassing contract development and manufacturing organizations specifically dedicated to cell and gene therapies has seen remarkable, rapid expansion lately. Projected to increase from a value of $5.41 billion in 2024 up to $6.92 billion by 2025, this expansion reflects a substantial compound annual growth rate of 27.9%. This past growth trajectory has been fueled by several key factors, including considerable strides in technology, supportive governmental regulations, rising capital injections, the widespread occurrence of hereditary conditions, and a growing number of collaborative alliances.

What's the Projected Size of the Global Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market by 2029?
Exponential expansion is anticipated for the market encompassing contract development and manufacturing organizations specializing in cell and gene therapies over the coming years, projected to reach a valuation of $17.57 billion by 2029, fueled by a compound annual growth rate (CAGR) of 26.2%; this upward trajectory during the forecast window is largely attributable to broadening therapeutic uses, progressive regulatory frameworks, greater financial allocations, advancements in technology, and heightened international partnerships, while key market developments are set to involve escalating requirements for individualized treatments, advances in automated and digital processes, the scaling up of production capabilities, the introduction of new methods for delivery, and a stronger emphasis placed on ecological responsibility and sustainability.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cell-and-gene-therapy-contract-development-and-manufacturing-organization-cdmo-global-market-report

Top Growth Drivers in the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Industry: What's Accelerating the Market?
The increasing incidence of cancer is anticipated to act as a primary catalyst for the expansion of the cell and gene therapy contract development and manufacturing organization (CDMO) sector moving ahead. Cancer, defined by the unrestrained proliferation and dissemination of aberrant cells within an organism, is on the rise due to factors such as an aging global demographic, shifts in daily habits, environmental contact, and enhanced diagnostic capabilities. Cell and gene therapy CDMOs contribute to mitigating the burden of cancer by engineering and producing sophisticated, focused therapies designed to boost treatment effectiveness and improve results for those affected. To illustrate this trend, data released by Macmillan Cancer Support, a charity based in the United Kingdom, demonstrated in October 2022 that the estimated population managing cancer within the UK is forecasted to climb from three million individuals in 2022 to reach 3.5 million by 2025, further rising to four million by 2030, and ultimately hitting 5.3 million by the year 2040. Consequently, the escalating rate of cancer occurrences directly stimulates the expansion witnessed in the cell and gene therapy CDMO market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15753&type=smp

What Trends Will Shape the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Through 2029 and Beyond?
Key players within the cell and gene therapy contract development and manufacturing organization sector are prioritizing the broadening of their offerings by incorporating sophisticated methodologies like the PluriMatrix technology, aiming to boost the throughput, effectiveness, and caliber of manufacturing processes for cell-based goods. This proprietary PluriMatrix system is specifically engineered to enable the high-volume generation of cellular products, facilitating the three-dimensional proliferation of cells at an industrial magnitude, thereby guaranteeing superior yields and dependable product specifications via a process that is entirely automated, meticulously regulated, and fully validated. Demonstrating this trend, in the month of January 2024, the Israeli biotechnology firm Pluri inaugurated PluriCDMO, a novel operational segment dedicated to providing cell therapy production services as a CDMO entity, featuring a substantial 47,000 square feet facility compliant with good manufacturing practice (GMP) standards for cell therapy production. This newly created branch within Pluri is equipped to deliver comprehensive support throughout the entire product lifecycle, spanning from initial preclinical research right through to late-phase clinical testing and eventual market launch, encompassing process and analytical refinement, scale-up validation, handling of logistics, automation integration, and necessary regulatory comparability assessments, as disclosed by the organization; fundamentally, these specialized cell therapy manufacturing services are delivered utilizing Pluri's state-of-the-art PluriMatrix platform.

What Are the Main Segments in the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?
The cell and gene therapy contract development and manufacturing organization (cdmo)market covered in this report is segmented -

1) By Product Type: Gene Therapy; Gene-Modified Cell Therapy; Cell Therapy
2) By Phase: Phase 1; Phase 2; Phase 3; Phase 4
3) By Indication: Oncology; Infectious Diseases; Neurological Disorders; Rare Diseases; Other Indications

Subsegments:
1) By Gene Therapy: Viral Vector-Based Gene Therapy; Non-Viral Gene Therapy; Plasmid DNA-Based Gene Therapy
2) By Gene-Modified Cell Therapy: CAR-T Cell Therapy; TCR-T Cell Therapy; NK Cell Therapy
3) By Cell Therapy: Stem Cell Therapy; Progenitor Cell Therapy; Immune Cell Therapy

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=15753&type=smp

Which Top Companies are Driving Growth in the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market?
Major companies operating in the cell and gene therapy contract development and manufacturing organization (CDMO) market are Pfizer Inc., Merck & Co. Inc., Thermo Fisher Scientific Inc., Novartis AG, FUJIFILM Diosynth Biotechnologies, AGC Biologics, Ajinomoto Co Inc., Lonza Group, Catalent Inc., Charles River Laboratories International Inc., Sartorius Stedim Biotech, Samsung Biologics Co Ltd., WuXi Biologics, Recipharm AB, Almac Group Ltd., KBI Biopharma, Rentschler Biopharma, Bio Elpida, Oxford BioMedica Plc, Avid Bioservices Inc., Cell and Gene Therapy Catapult, VGXI Inc., Genezen Laboratories Inc., Pluri Inc., OmniaBio Inc.

Which Regions Will Dominate the Cell And Gene Therapy Contract Development And Manufacturing Organization (CDMO) Market Through 2029?
North America was the largest region in the cell and gene therapy contract development and manufacturing organization (CDMO) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell and gene therapy contract development and manufacturing organization (CDMO) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15753

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.